共查询到20条相似文献,搜索用时 93 毫秒
1.
2.
3.
4.
目的:探讨下肢股浅动脉长段闭塞的治疗方式。方法:回顾性分析2010年1月~2013年1月我院收治的29例下肢股浅动脉长段闭塞手术治疗病人的资料,总结分析下肢股浅动脉长段闭塞治疗的方式。结果:本组29例病例,腔内介入治疗17例,传统外科旁路手术12例;术后随访,失访4例,23例获得随访,术后6月通畅率为87%(20/23),术后12月通畅率为85%(17/20),术后12月保肢率为95%。结论:对于下肢股浅动脉长段闭塞病变病人,腔内介入治疗和传统外科旁路手术治疗都是有效方式,应该将腔内手术及传统外科旁路手术的优缺点结合起来,优势互补,兼顾减低麻醉、围手术期及手术风险,以达到中远期较好的通畅率。 相似文献
5.
目的:探讨介入治疗在下肢动脉闭塞性疾病中的临床应用价值。方法:分析21例(38条患疾下肢)双侧髂动脉和髂动脉近端狭窄闭塞及累及股浅动脉狭窄闭塞经肱动脉穿刺应用腔内血管成形术及选择性血管内支架置入术后的临床疗效。结果:除1例3个月后继发动脉内血栓形成,其余病例经介入治疗后血管均开通,临床症状明显改善,踝/肱指数由0.19~0.62(平均0.42±0.15)上升为0.46~0.93(平均0.73±0.18)。结论:经肱动脉穿刺应用腔内血管成形术及选择性支架置入为主的综合介入治疗是治疗双侧髂动脉和髂动脉近端狭窄闭塞及累及股浅动脉狭窄闭塞疾病的有效治疗方法,但需严格掌握其适应证。 相似文献
6.
7.
8.
9.
10.
目的探讨采用介入方法治疗下肢动脉闭塞性病变的临床策略。方法 2001年2月至2009年11月期间我院介入病房收治的76例经数字减影血管造影(DSA)证实为髂动脉和/或股动脉闭塞的患者,男性45例,女性31例,年龄32~85岁。闭塞段长度1~40 cm,发病时间10 h至30年。术中分别采用经导管动脉内溶栓、导丝机械开通、经皮血管腔内成形术(PTA)、支架置入术等方法,术后给予抗凝及抗炎治疗1周,随访12个月至5年。结果总的技术成功率为97%(74/76)。本组治疗中,溶栓治疗26例,机械开通65例,PTA68例,支架置入62例。术中未出现血管破裂、穿孔等严重并发症。术后所有患者下肢缺血症状明显减轻或消失。随访期间11例患者再次出现下肢缺血症状。其余62例症状无复发,血管超声复查提示管腔通畅、血流良好。结论介入治疗肢体动脉闭塞性病变创伤小、疗效好,具有良好的临床应用价值。 相似文献
11.
Yin Xia Dan Shang Qin Li Xiaoqin Run Chenxi Ouyang Yiqing Li Bi Jin 《Frontiers of Medicine in China》2009,3(2):240-244
Severe diffuse cavernous hemangioma of the lower limb is rarely seen among young people and sometimes can be a fatal challenge
for operation. We reported a case of diffuse cavernous hemangioma involving both skin and muscles of the left lower limb and
perineal region in an adolescent patient. The patient who had previously undergone a local hemangioma resection of the foot
ultimately ended in superficial femoral artery ligation and supergenual thigh amputation of the left upper leg because of
uncontrollable massive bleeding of anastomotic stoma. 相似文献
12.
目的 探讨股浅静脉戴戒术治疗中重度原发性下肢深静脉瓣膜功能不全的疗效。方法 对54例原发性下肢深静脉瓣膜功能不全患者进行下肢深静脉顺逆行造影,提示倒流程度均为2~4级,通过分析,将其分为深静脉显著增粗但瓣膜瓣叶的游离缘并未严重受损及瓣膜瓣叶的游离缘严重受损2类,并对深静脉显著增粗但瓣膜瓣叶的游离缘并未严重受损32例进行股浅静脉戴戒术。结果 疗效良好29例、占90.6%,好转者3例、占9.4%,全部患者症状消失,溃疡愈合,多普勒超声示静脉无明显血液倒流。结论 股浅静脉戴戒术是治疗瓣膜瓣叶未严重受损的中重度原发性下肢深静脉瓣膜功能不全的有效方法,静脉造影是判断手术适应证的重要依据。 相似文献
13.
目的 探讨原发性下肢深静脉瓣膜功能不全的手术治疗方法及效果.方法对原发性下肢深静脉瓣膜功能不全12例患者施行股浅静脉壁环形缩窄术,并同时行浅静脉手术.结果患者浅静脉曲张,下肢沉重及肿胀均消失,足靴区溃疡愈合,无继发血栓形成.结论股浅静脉壁环形缩笮术治疗原发性下肢深静脉瓣膜功能不全,手术简便,并发症少. 相似文献
14.
目的探讨复方樟柳碱颞浅动脉旁皮下注射治疗视神经挫伤的疗效。方法20例(22只眼)视神经挫伤患者为治疗组,采用复方樟柳碱2ml患侧颞浅动脉旁皮下注射,每日1次,每疗程14d,3个疗程。另18例(20只眼)视神经挫伤患者为对照组,除不加用复方樟柳碱外,其他用药同治疗组疗效观察指标为视力、视野。结果治疗组总有效率为86%,对照组为45%.两组比较具有显著的统计学差异(P〈0.05)。结论颞浅动脉旁皮下注射复方樟柳碱注射液治疗视神经挫伤有明显疗效,且毒副作用小,安全性高,值得临床推广应用。 相似文献
15.
目的探讨髂动脉闭塞性病变介入治疗的技术要点。方法本组41例髂动脉闭塞的患者通过行闭塞段开通、经导管局部溶栓、血管腔内成形术(PTA)和内支架置入等多种介入方法综合治疗来观察效果。结果 41例患者介入治疗成功率达100%,治愈36例,好转5例,共9例血管闭塞者进行了溶栓治疗。术后随访2~24个月,平均18个月,除2例分别在术后11个月和8个月发生支架内再闭塞行二次介入治疗外,其余患者症状均无加重或复发。结论血管腔内介入治疗可作为治疗髂动脉闭塞可选择的手术替代方案,尤其是对于有高手术风险的患者,具有微创、简单、有效的优点。 相似文献
16.
17.
《Current medical research and opinion》2013,29(10):1661-1670
SUMMARYThis paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays in its treatment. IC is a common and debilitating condition that has a significant adverse impact on health-related quality of life (HR-QoL). It is currently under-recognised as a powerful marker of increased cardiovascular (CV) risk. The clinical priority is secondary prevention – sometimes referred to as best medical therapy aimed at reducing CV risk. However, the priority for most patients (often overlooked by clinicians) is symptom relief: an increase in walking distance leading to an improvement in HR-QoL. The symptoms of IC may be improved by exercise, pharmacotherapy, and when these are unsuitable or unsuccessful, endovascular or surgical intervention. 相似文献
18.
目的:比较髓内固定系统与钉板固定系统治疗股骨粗隆骨折的临床效果。方法选取2010年2月~2013年10月本院收治的股骨粗隆骨折患者74例,随机将患者分为PFN组和DHS组,每组37例,比较两组的骨折愈合程度和手术相关指标。结果与DHS组患者相比,PFN组的优良率明显提高,可达97.30%,手术时间和骨折愈合时间明显缩短,术中出血量明显减少,两组比较,差异有统计学意义(P<0.05)。结论髓内固定系统对于股骨粗隆的治疗效果优于钉板固定系统,但两者远期效果的比较则需进一步临床验证。 相似文献
19.
20.
《Expert opinion on drug delivery》2013,10(10):1489-1499
ABSTRACTIntroduction: Every decade the field of interventional cardiology is revolutionized by new technology. The fully bioresorbable everolimus-eluting scaffold (ABSORB BVS) technology would preserve the benefits of metallic stents by sealing balloon-induced dissections, avoiding elastic recoil and vessel occlusion. The polymeric scaffold would be resorbed to restore the natural integrity of the vessel, superseding the consequence of the permanent presence of a foreign body in the coronary artery.Areas covered: This technology evaluation focuses on the clinical evidence for the use of bioresorbable everolimus-eluting scaffold for the treatment of coronary artery disease.Expert opinion: The current generation of the bioresorbable scaffold has structural and mechanical limitations that might preclude the widespread use in clinical practice. The strut thickness (150 µm) limits deliverability and creates laminar flow disruptions that might be the nidus of an increased rate of scaffold thrombosis. In the next generation of bioresorbable scaffolds, the resorption process should be faster and in particular, strut thickness must be reduced. This will probably represent a significant step forward in an attempt to increase the efficacy and safety profile of the device and achieve a similar performance with the current generation drug-eluting stent even in complex scenarios. 相似文献